Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Research from McMaster University, Division of Clinical Immunology yields new data on immunotherapy
April 11th, 2007
Research findings, "Peptide immunotherapy for allergic diseases," are discussed in a new report. According to recent research from Hamilton, Canada, "Specific allergen immunotherapy has been widely practised for almost 100 years. Whilst this approach is disease-modifying and efficacious, the use of whole allergen preparations is associated with an unacceptably high prevalence of allergic adverse events during treatment." "Many approaches to reduce the allergenicity of immunotherapy preparations whilst maintaining immunogenicity are under development. One such approach is the use of short synthetic peptides which represent major T-cell epitopes of the allergen. Major...
Source: Immunotherapy Weekly (2007-04-11)
|
